| First Author | Elizondo DM | Year | 2016 |
| Journal | J Leukoc Biol | Volume | 100 |
| Issue | 5 | Pages | 855-864 |
| PubMed ID | 27317750 | Mgi Jnum | J:319217 |
| Mgi Id | MGI:6863190 | Doi | 10.1189/jlb.2HI1115-525R |
| Citation | Elizondo DM, et al. (2016) Dendritic cell expression of ADAM23 governs T cell proliferation and cytokine production through the alpha(v)beta(3) integrin receptor. J Leukoc Biol 100(5):855-864 |
| abstractText | ADAM23 is a member of the brain macrophage-derived chemokine family. Structural homology of ADAM proteins suggests their function as integrin receptors. Previous studies have linked ADAM23 as a dominant contributor to brain development and cancer metastasis. The present studies now show that ADAM23 expression on DCs partially governs antigen-presentation capacities to responder CD4(+) T cells. With the use of RNAi approaches, knockdown of ADAM23 in murine BMDCs resulted in impaired T cell activation, proliferation, and cytokine production. Knockdown did not alter the maturation profile of DCs (i.e., costimulatory molecule expression or production of proinflammatory cytokines) but markedly impaired cognate T cell responses. There was a significant decrease in antigen-specific clonal expansion coupled with a global decrease in Th cytokine production. Impaired early activation and proliferation did not alter/skew the balance of Th polarization but significantly depressed total levels of IL-2, IFN-gamma, IL-4, and IL-17 cytokine production in CD4(+) T cells primed by ADAM23 knockdown versus control DCs. Finally, neutralizing antibodies targeting the alpha(v)beta(3) integrin receptors resulted in similar phenotypes of impaired CD4(+) T cell responses. Taken together, these studies show a novel role of ADAM23 in governing DC antigen presentation to cognate CD4(+) T cells. |
